Atozin drugs – Atozin Fandel http://atozinfandel.com/ Fri, 25 Nov 2022 08:10:07 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://atozinfandel.com/wp-content/uploads/2022/02/icon-2022-02-01T191236.650-150x150.jpg Atozin drugs – Atozin Fandel http://atozinfandel.com/ 32 32 Growing demand for generic drugs propels Global Aseptic Pharma https://atozinfandel.com/growing-demand-for-generic-drugs-propels-global-aseptic-pharma/ Fri, 25 Nov 2022 07:14:00 +0000 https://atozinfandel.com/growing-demand-for-generic-drugs-propels-global-aseptic-pharma/ Aseptic Pharmaceutical Processing and Packaging Equipment Market According to a new market research report launched by Inkwood Research, the global aseptic pharmaceutical processing and packaging equipment market is expected to reach a revenue of $13,902.4 million by 2028, growing at a CAGR of 7.12% over the forecast period 2021-2028. Browse 65 market data tables and […]]]>

Aseptic Pharmaceutical Processing and Packaging Equipment Market

According to a new market research report launched by Inkwood Research, the global aseptic pharmaceutical processing and packaging equipment market is expected to reach a revenue of $13,902.4 million by 2028, growing at a CAGR of 7.12% over the forecast period 2021-2028.

Browse 65 market data tables and 50 figures spread over 210 pages, as well as an in-depth analysis of the global aseptic pharmaceutical processing and packaging equipment market by component, application and geography

This insightful market research report by Inkwood Research focuses on market trends, major players, supply chain trends, technological innovations, key developments and future strategies. The report covers all aspects of this comprehensive market by assessing major geographies and is a valuable asset for existing players, new entrants and future investors. The study presents a detailed analysis of the market, with contributions from industry professionals across the value chain.

Global Aseptic Pharmaceutical Processing and Packaging Equipment Market Scenario

Aseptic processing involves the sterilization and cleaning of touch surfaces such as the product, machine components, enclosure, and container prior to manufacturing.

In recent years, several leading drugs have lost their patents, facilitating the entry of low-cost generic counterparts. Additionally, rising prevalence of chronic diseases, rising healthcare expenditures, and introduction of new drugs are benefiting the growth of the global aseptic pharmaceutical processing equipment market. Also, the pandemic has seen an increasing demand for several generic drugs like multivitamins, steroids, antivirals, antibiotics, etc. This further influenced the increase in production capacity with the Good Manufacturing Practice (cGMP) guidelines.

In addition, the increase in drug sales volume is attributed to higher sales of biopharmaceutical and generic counterparts of branded drugs. Additionally, the need for efficient aseptic processing and packaging systems owing to the growing demand for pharmaceutical drugs is driving the growth of the market. However, high costs and lack of qualified personnel are hampering the growth of the market.

The Global Aseptic Pharmaceutical Processing and Packaging Equipment Market report provides tabulated data and includes tables and graphs for visual analysis.
Request a Free Sample Report for the Global Aseptic Pharmaceutical Processing and Packaging Equipment Market by Component, Application and Geography: https://inkwoodresearch.com/reports/aseptic-pharma-processing-and-packaging-equipment-market/#request-free-sample

Market segmentation

Market by component
• Packaging equipment
o Inspection machines
o Aseptic packaging machines
o Labellers
• Processing equipment
o Mixing equipment
o Feeders
o Filling/finishing equipment
o Extruders
o Mills
o Pneumatic conveying equipment
o Granulation equipment
o Tablet compression equipment
o Drying equipment

Market by Application
• Ophthalmic suspensions
• Sterile injectables
• Reconstituted lyophilized powders for injection
• Aqueous aerosols for inhalation
• Other applications

Report Highlights

– The report provides detailed analysis of current and future market trends to identify investment opportunities
– Market forecast to 2030, using estimated market values ​​as base figures
– Key market trends across business segments, regions and countries
– Main developments and strategies observed on the market
– Market dynamics such as drivers, restraints, opportunities and other trends
– Detailed company profiles of key players and upcoming top players
– Growth prospects for emerging countries until 2030

Profiled companies

• GEA GROUP
• INDUSTRIA AUTOMATIC SPA MACHINE
• DUPONT
• SANITARY
• AMCOR APIs
• TACOMA LLC AUTOMATED SYSTEMS (AST)
• ROMELAG
• SPX FLOW INC.
• STERILINE
• GREATVIEW ASEPTIC PACKAGING CO LTD
• NICOS GROUP
• JOHN BEAN TECHNOLOGIES CORPORATION (JBT)
• BIOPHARMA GROUP
• BECTON, DICKINSON AND COMPANY (COMIC)
• ROBERT BOSCH GMBH

Related Reports

GLOBAL CONTINUOUS PHARMACEUTICAL MANUFACTURING MARKET –
https://inkwoodresearch.com/reports/pharmaceutical-continuous-manufacturing-market/
The global pharmaceutical continuous manufacturing market is expected to grow at a CAGR of 10.23% during the period 2021-2028.

GLOBAL PHARMACEUTICAL FILTRATION MARKET –
https://inkwoodresearch.com/reports/pharmaceutical-filtration-market/
The global pharmaceutical filtration market is expected to register a CAGR of 8.48% between 2021 and 2028.

GLOBAL MEDICAL AND LABORATORY REFRIGERATORS MARKET –
https://inkwoodresearch.com/reports/medical-and-lab-refrigerators-market/
The global medical and laboratory refrigerators market is expected to project a CAGR of 4.14% during the forecast period 2021-2028.

Inkwood Research
169 Harrison Avenue
Boston, MA 02111
Tel: 1-(857)293-0150
Email: sales@inkwoodresearch.com
Website: www.inkwoodresearch.com

At Inkwood Research, we not only provide you with consulting services, but also syndicated and custom research reports that help you move your business forward.

This press release was published on openPR.

]]>
At 15% CAGR, the Short Bowel Syndrome Drugs Market is worth USD 4.40 https://atozinfandel.com/at-15-cagr-the-short-bowel-syndrome-drugs-market-is-worth-usd-4-40/ Thu, 24 Nov 2022 11:50:00 +0000 https://atozinfandel.com/at-15-cagr-the-short-bowel-syndrome-drugs-market-is-worth-usd-4-40/ The Short Bowel Syndrome Drugs market report includes the most recent market information with which the companies can have an in-depth analysis of healthcare sector and future trends. By applying market intelligence for this report, industry experts assess strategic options, outline successful action plans, and support businesses in critical outcome decisions. The competitive analysis studies […]]]>

The Short Bowel Syndrome Drugs market report includes the most recent market information with which the companies can have an in-depth analysis of healthcare sector and future trends. By applying market intelligence for this report, industry experts assess strategic options, outline successful action plans, and support businesses in critical outcome decisions. The competitive analysis studies of this credible market report help to get an idea of ​​the strategies of the major players in the market. Not to mention, the scope of the Short Bowel Syndrome Drugs market research report can be broadened from the market scenarios to the comparative prices among key players, costs, and profits of the specified market regions.

The high-quality Short Bowel Syndrome Drugs market report helps companies in all areas of trade to make first-class decisions, solve the toughest business questions, and reduce the risk of failure . Important highlights of this market report are key market dynamics, current market scenario and future industry outlook. The Short Bowel Syndrome Drugs marketing report is an absolute overview of the market which covers various aspects such as product definition, usual vendor landscape and market segmentation based on various parameters such as type of product, its components, type of management and geography.

Download a sample PDF copy of this report to understand the structure of the full report (including full TOC, Table and Figures)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-short-bowel-syndrome-drugs-market

Major key players operating in the Short Bowel Syndrome Drugs Market include:
• Takeda Pharmaceutical Company Limited (Japan)
• Johnsons & Johnsons Services Inc (United States)
• Boehringer Ingelheim International GmbH (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Sanofi (France)
• GSK Plc. (UK)
• Novartis AG (Switzerland)
• Pfizer Inc. (United States)
• Amneal Pharmaceuticals LLC. (WE)
• Alvogen (USA)

Key market analysis and insights:

Short bowel syndrome is linked to small bowel surgeries. It is usually acquired during the individual’s lifetime and only occurs genetically in a few cases. Currently, there is no cure for short bowel syndrome and treatment is focused on its symptoms. In some cases, short bowel syndrome can be life-threatening, but the condition can be managed with effective medication. In addition, government authorities participate directly in strengthening the confidence of local manufacturers through various initiatives.

Data Bridge Market Research analyzes a growth rate of the global Short Bowel Syndrome Drugs market over the forecast period 2022-2029. The expected CAGR of the global Short Bowel Syndrome Drugs market is typically around 15% during the mentioned forecast period. The market was valued at USD 1.44 Billion in 2021, and it will reach USD 4.40 Billion by 2029. Along with insights into the market scenarios such as market value, growth rate, segmentation, Geographical coverage and major players, market reports curated by Data Bridge Market Research also includes in-depth expert analysis, patient epidemiology, pipeline analysis, price analysis, and regulatory framework.

Browse the full report with facts and figures @ https://www.databridgemarketresearch.com/reports/global-short-bowel-syndrome-drugs-market

Global Short Bowel Syndrome Drugs Market Scope and Market Size

The global short bowel syndrome drugs market is segmented on the basis of drug class, route of administration, distribution channel, and end-user. The growth among these segments will help you analyze weak growth segments in the industries and provide users with valuable market insight and market insights to help them make strategic decisions to identify major applications of the market.

Drug class
• Glucagon-like peptide
• Anti-diarrheal
• Histamine blockers
• Proton pump inhibitors
• Growth hormone
• Others

Route of administration
• Oral
• Parenteral
• Others

Final user
• Hospitals
• Home Care
• Specialized clinics
• Others

Distribution channel
• Hospital pharmacy
• Online pharmacy
• Retail pharmacy

Short Bowel Syndrome Drugs Market, By Region:

The global Short Bowel Syndrome Drugs market is analyzed and market size insights and trends are provided by country, product as listed above.

The countries covered in the Short Bowel Syndrome Drugs market report are US, Canada, Mexico North America, Germany, France, UK, Netherlands , Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia , Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) in Middle East and Africa (MEA) frame, Brazil, Argentina and Rest of South America in South America frame.

North America is dominating the short bowel syndrome drugs market due to increasing cases of arrhythmic diseases, favorable reimbursement policies for patients, high demand for advanced treatment methods and health infrastructure developed in the region. Asia-Pacific is estimated to witness growth during the forecast period due to high prevalence of cardiovascular diseases, increased adoption of advanced digital devices, large population and launch new innovative products.

Ask before you buy this research report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-short-bowel-syndrome-drugs-market

Global Short Bowel Syndrome Drugs Market Dynamics

Drivers

• Increased demand for intravenous fluid supplementation
There is a growing demand for intravenous fluid supplementation to maintain normal hydration and urine flow in patients with this syndrome. Several key manufacturers in the short bowel syndrome market are striving to meet this demand as these patients suffer from complications such as hyponatremia, dehydration, and chronic kidney failure. Hypomagnesemia is caused by magnesium malabsorption due to loss of the distal ileum, several manufacturers produce magnesium supplements to help patients achieve adequate hydration.

• Prevalence of short bowel syndrome
The incidence of short bowel syndrome has been increasing worldwide in recent years. The increasing number of patients on total parenteral nutrition has led to an increase in market growth. The occurrence of short bowel syndrome is expected to be around four people per million, and the occurrence is around three people per million. Although the exact prevalence of the disease is unclear, it is expected based on the number of people on parenteral nutrition.

Research methodology :
Base year data collection and analysis is done using data collection modules with large sample sizes. Market data is analyzed and estimated using statistical and consistent market models. In addition, market share analysis and key trend analysis are key success factors for the market report. To learn more, please request an analyst call or can submit your request. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables in the market and primary validation (industry expert ). Apart from this, data models include Vendor Positioning Grids, Market Timeline Analysis, Market Overview & Guide, Company Positioning Grid, Share Analysis of the company’s market, the standards of measurement, the global analysis compared to the part of the suppliers. To learn more about the research methodology, submit a request to speak to our industry experts.

Table of Contents: Global Short Bowel Syndrome Drugs Market
1. Introduction
2 Market Segmentation
3 Executive summary
4 Premium Preview
5 Market Overview
6 Impact of Covid-19 on Short Bowel Syndrome Drugs in Healthcare Industry
7 Global Short Bowel Syndrome Drugs Market, by Product Type
8 Global Short Bowel Syndrome Drugs Market, By Modality
9 Global Short Bowel Syndrome Drugs Market, by Type
10 Global Short Bowel Syndrome Drugs Market, By Mode
11 Global Short Bowel Syndrome Drugs Market, by End User
12 Global Short Bowel Syndrome Drugs Market, By Geography
13 Global Short Bowel Syndrome Drugs Market, Company Landscape
14 Swot Analysis
15 company profiles
16 Quiz
17 related reports

Check the complete table of contents with the list of tables and figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-short-bowel-syndrome-drugs-market

About Us:

Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting company with an unparalleled level of resilience and integrated approaches. We are committed to unearthing the best market opportunities and fostering effective information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge is expert in creating satisfied customers who rely on our services and rely on our hard work with certainty. Get customization and discount on the report by emailing sopan.gedam@databridgemarketresearch.com. We are pleased with our glorious 99.9% customer satisfaction rating.

Contact us:-
Data Bridge Market Research
USA: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This press release was published on openPR.

]]>
Addicts spend Rs 11 lakh monthly on drugs: IMHANS study https://atozinfandel.com/addicts-spend-rs-11-lakh-monthly-on-drugs-imhans-study/ Wed, 23 Nov 2022 19:59:30 +0000 https://atozinfandel.com/addicts-spend-rs-11-lakh-monthly-on-drugs-imhans-study/ Srinagar: In a shocking revelation, drug addicts in Kashmir are consuming drugs worth Rs 11 lakh every month, a survey by the Institute of Mental Health and Neuroscience (IMHANS), Kashmir reveals. According to the ‘Prevalence and Pattern of Substance Use in 10 districts of Kashmir: A 2022 survey’ conducted by IMHANS, Rs 9 lakh is […]]]>

Srinagar: In a shocking revelation, drug addicts in Kashmir are consuming drugs worth Rs 11 lakh every month, a survey by the Institute of Mental Health and Neuroscience (IMHANS), Kashmir reveals.

According to the ‘Prevalence and Pattern of Substance Use in 10 districts of Kashmir: A 2022 survey’ conducted by IMHANS, Rs 9 lakh is worth heroin, Rs 1 lakh cannabis and Rs 1.30 lakh pharmaceutical opioids are consumed in Kashmir every month. .

Kashmir has about 67,468 drug addicts.

Kulgam district tops the list with abusers spending Rs 1,01,660 on heroin every month while it was lowest in Baramulla district at Rs 71,020.

According to the data, heroin worth Rs 89,134 was consumed in Anantnag, Rs 1,00,202 in Bandipora, Rs 88,995 in Baramulla, Rs 74,694 in Budgam, Rs 87,392 in Kupwara, Rs 88,529 in Srinagar, Rs 1,00,165 to Shopian and Rs 81,726 to Pulwama.

Similarly, for cannabis, Ganderbal said he spent the least at Rs 2,415 and Kupwara said he spent the most at Rs 23,272.

For pharmaceutical opioids, Baramulla said to have spent the least with Rs 5,083 and Bandipora was said to have spent the highest at Rs 22,264.

According to the survey, substance use is prevalent among young men.

“The mean age of substance users was 28.15 years with a standard deviation of 7.44 and substance use was observed mainly among the unemployed population (25.2%),” the study found. .

Furthermore, opioids were the most commonly used psychoactive substance in all districts of Kashmir, with heroin being the predominant opioid.

According to doctors at IMHANS-K, the average heroin consumption is 1-2 grams per day which costs them around Rs 3000 to Rs 6000.

“As heroin is expensive, to meet the expenses, they engage in various illegal activities, starting with stealing from their family members, selling their gadgets, incurring debts, thefts and also engaging in trafficking drugs,” they said.

“Unfortunately, if we see, the increase in crime may be a consequence of substance use, but we don’t have to criminalize it. We are already aware of the associated health burden, but it also represents a huge economic burden for an individual and the society as a whole.This economic burden also creates a huge revenue generating market for those involved in this business.If we see across the world, the drug related market is the third largest business with a turnover of 500 billion US dollars.

]]>
These 5 animals also travel with psychedelic and psychoactive drugs https://atozinfandel.com/these-5-animals-also-travel-with-psychedelic-and-psychoactive-drugs/ Tue, 22 Nov 2022 22:04:02 +0000 https://atozinfandel.com/these-5-animals-also-travel-with-psychedelic-and-psychoactive-drugs/ At the end of last month, the United States National Park Service invited its visitors toplease don’t lick” the toads that inhabit its parks. While the invitation surely applied to toads of all shapes, sizes, and species, it specifically targeted the Sonoran Desert Toad., a large, tough amphibian famous for secreting a special super-toxic substance […]]]>

At the end of last month, the United States National Park Service invited its visitors toplease don’t lick” the toads that inhabit its parks. While the invitation surely applied to toads of all shapes, sizes, and species, it specifically targeted the Sonoran Desert Toad., a large, tough amphibian famous for secreting a special super-toxic substance so scared.

In addition to his toxicity, this poison, commonly known as “Five” or “Bufo”, also has intense psychoactive properties if scraped from the skin of toads and smoked. Apparently, the visions and sensations produced by this process are so strong and pleasurable that people are beginning to give up scratching and smoking and instead go straight to the source.

Although it is unclear whether touching the tongue to the toad produces the same type or force of travel as the traditional method of inhalation, the interest of these individuals in toad licking is part and parcel of a phenomenon. much larger, not just for our own species.

In fact, history shows that Homo sapiens have always handled an assortment of psychoactive substances, drawn from plant and animal sources for the purpose of pleasure or pain relief. However, humans are not the The only ones in search of psychotropic materials.

Here are five types of animals that enjoy a natural type of high.

1. Cats and catnip

(Credit: Alan Tunnicliffe)

From the adorable lumps that live on our couches to the lions, leopards and lynxes that live in the wild, cats are known to love catnip. The plant appears all over the world, producing a chemical called nepetalactone. Whether inhaled or injected, this chemical puts cats in a daze, causing them to sniff, stretch, roll and rub without thinking. Some scientists think the plant also produces hallucinations, as some cats crush or stalk imaginary prey under its influence.

Several types of cats seek out other psychoactive substances to supplement their catnip craze. Jaguars, for example, are also fans of the active psychoactive agents of ayahuasca, also known as yagé. The indigenous peoples of the Amazon Basin brew this type of plant into a drink and sip it as spiritual aid. But for jaguars, the same ingredients make for clumsy, laid-back big cats.

2. Deer and Mushrooms

In Siberia, Scandinavia, and similar regions, several species of deer, including moose and reindeer, are known to munch on flying amanita mushrooms while foraging for food in winter. These mushrooms contain a sedative compound called muscimol and can cause animals to act almost as if they are drunk, move around and make strange sounds.

Amazingly, the psychoactive properties of these mushrooms intensify during digestion, infusing animal urine with psychoactive potency. Experts say that the deer of these regions, as well as several native tribes, have realized that they can ingest this intensified substance. It creates a much more powerful effect than that resulting from simply consuming the mushroom.

3. Dolphins and puffer fish

Around the Atlantic Azores Islands in the 1990s, scientists have seen several dolphins catch, nibble and pass around a puffed up pufferfish for the first of a few times. Stress inhalers produce a potent poison that puts predators into a temporary trance if ingested in small amounts. And the specialists finally assumed that the dolphins intentionally terrified the inhaler into squirting out the intoxicant.

Since the toxin, tetrodotoxin, is deadly in substantial doses, scientists say dolphins pass pufferfish from one individual to another with extreme caution, instilling in the philosophy of “puff, puff pass “stoner a whole new meaning. After nibbling and prodding these fish, the dolphins then float around aimlessly, gazing at the surface of the water with appropriate fascination.

4. Bighorn sheep and lichen

(Credit: Andrea Izzotti/Shutterstock)

Sheep are famous for consuming almost any plant available on their pastures. However, say the scientists that animals are also known to stray from their traditional foraging territories to satisfy their insatiable desire for lichen. In fact, big horn sheep frequently stray from their herds and travel dangerous trails to find their favorite form of lichen, an addictive combination of algae and fungi that only exists in extreme environments.

Once they locate this hallucinogenic lichen high up in their Rocky Mountain home, the sheep then scrape the substance off the rocks with their teeth, wearing down their teeth in the process.

5. Wallaby and poppies

(Credit: Rizd/Shutterstock)

In Australia and on the Australian island of Tasmania, a number of farmers have found wallabies stuffing themselves in fields of poppies, which are grown as an active ingredient in prescription painkillers.

After consuming the poppies, state of observers that the little creatures circle around until they “crash”, sometimes resulting in crop circles, and eventually return to the fields again and again to feast on the psychoactive plants.

]]>
Antimanic Drugs Market Size, Opportunities Generated, Future Outlook 2022-2028 | Eli Lilly and Company, Sumitomo Dainippon Pharma, Ltd, Allergan https://atozinfandel.com/antimanic-drugs-market-size-opportunities-generated-future-outlook-2022-2028-eli-lilly-and-company-sumitomo-dainippon-pharma-ltd-allergan/ Tue, 22 Nov 2022 10:56:36 +0000 https://atozinfandel.com/antimanic-drugs-market-size-opportunities-generated-future-outlook-2022-2028-eli-lilly-and-company-sumitomo-dainippon-pharma-ltd-allergan/ Coherent Market Insights has published a new study on “Antimanic Drugs Market” which aims to provide an in-depth review of factors influencing global business introduction and outlook. The detailed information and overview of the Global Antimanic Drugs market report highlights the latest trends across various regions. Major market players will benefit from the business insights […]]]>

📝Coherent Market Insights has published a new study on “Antimanic Drugs Market” which aims to provide an in-depth review of factors influencing global business introduction and outlook. The detailed information and overview of the Global Antimanic Drugs market report highlights the latest trends across various regions. Major market players will benefit from the business insights provided in this report. The Antimanic Drugs Market research report is an intelligence report that includes accurate and valuable data on market size, developing countries, market share and revenue forecast till 2028. It also provides information on market development and capabilities.

The Antimanic Drugs Market report helps a wide range of businesses to understand what their consumers really want by carrying out in-depth market research. When it comes to new products, every business owner wants to know about demand, and this report is a great resource. Additional benefits include ensuring that the latest market developments are covered. You can keep a close eye on the leading rivals and their business growth tactics by reading the Antimanic Drugs Market report. It also conducts extensive research for the years 2022-2028 to provide business owners with new business options.

Request here the sample copy of the report @
https://www.coherentmarketinsights.com/insight/request-sample/4143

This research also provides a dashboard view of leading organizations, highlighting their effective marketing tactics, market share, and most recent advancements in historical and current contexts.

⏩ Major key players in this market:

Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd, Allergan plc, Xian Janssen Pharmaceutical Ltd, Pfizer Inc., Otsuka Pharmaceutical, Taro Pharmaceutical Industries Ltd, Apotex Inc., Teva Pharmaceutical Industries Ltd and Torrent Pharmaceutical Ltd.

⏩ Antimanic Drugs Market Segmentation:

On the basis of the drug:

  • Lithium salts
  • Carbamazepine
  • Valproic acid
  • Lamotrigine
  • Olanzapine
  • Others

⏩ Market scope & Tendencies:

The report provides comprehensive market information to industry stakeholders, including an explanation of the complex market data in plain language, the history and current status of the industry, as well as size and trends expected from the market. The research studies all industry categories, focusing on key companies such as market leaders, followers and new entrants. The document includes a full PESTLE analysis for each country. A detailed picture of the competitive landscape of leading competitors in the Global Anti-Manicity Drugs Market by goods and services, revenue, financial position, portfolio, growth plans and geographical presence makes the study an investor’s guide.

For more information or query or customization before buying, visit @
https://www.coherentmarketinsights.com/insight/request-customization/4143

The objectives of the study are:

✔ A comprehensive overview of major players operating in the Antimanic Drugs market and their corresponding data.

✔ It includes product portfolio, annual revenue, research and development expenditure, geographic presence, key developments in recent years and growth strategies.

✔ Regional analysis, which includes an overview of the dominant market and the corresponding market share.

✔ It also includes various socio-economic factors affecting the development of the market in the region.

✔ The report offers a comprehensive overview of the various individuals in the value chains such as raw material suppliers, distributors and shareholders.

⏩ Key Opportunities:

The report examines the key opportunities in the Antimanic Drugs Market and identifies the factors that are and will continue to drive the growth of the industry. It takes into account past growth patterns, growth drivers, as well as current and future trends.

⏩ Regional outlook: The Antimanic Drugs Market report is highly structured into region wise study. The comprehensive regional analysis done by the researchers highlights the key regions and their dominant countries accounting for substantial revenue share in the market.

Purchase this full activity report (discount available up to 25%):
https://www.coherentmarketinsights.com/insight/buy-now/4143

⏩ Answers to key questions:

1. What is the market size and CAGR of the Antimanic Drugs market during the forecast period?
2. What is the impact of growing demand on Antimanic Drugs Market share growth?
3. What is the growing demand for Antimanic Drugs market during the forecast period?
4. Who are the main suppliers in the market and what are their market shares?
5. What is the impact of the COVID-19 pandemic on the APAC Antimania Drugs market?

to offer

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We are known for our actionable insights and genuine reports in various fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact us:

Mr Shah
Consistent market information
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, USA
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
E-mail: [email protected]

]]>
Tilton man admits swapping drugs meant for children https://atozinfandel.com/tilton-man-admits-swapping-drugs-meant-for-children/ Mon, 21 Nov 2022 22:24:00 +0000 https://atozinfandel.com/tilton-man-admits-swapping-drugs-meant-for-children/ A Tilton man has admitted to swapping children’s drugs at a residential facility, injuring two children.Thomas Poirier, 41, of Tilton, pleaded guilty on Monday to charges dating back to December 2020.Poirier was employed at Spaulding Academy and Family Services, a residential facility in Northfield. Prosecutors said an investigation was launched when a nurse discovered a […]]]>

A Tilton man has admitted to swapping children’s drugs at a residential facility, injuring two children.Thomas Poirier, 41, of Tilton, pleaded guilty on Monday to charges dating back to December 2020.Poirier was employed at Spaulding Academy and Family Services, a residential facility in Northfield. Prosecutors said an investigation was launched when a nurse discovered a missing Ritalin prescription from a controlled medication cart. Surveillance video shows Poirier inside the medication room, handling the cart. He is accused of taking Ritalin pills for several days and putting an unknown substance in their place. According to the state, about 20 children, including nine under the age of 13, took the pills. Because they did not receive the medication they needed, two of the children suffered severe physical and psychological harm, prosecutors said. Poirier pleaded guilty to two assault charges and one drug charge. He will be sentenced at a later date and prosecutors recommend a sentence of four to eight years in prison. Prosecutors praised Spaulding for acting immediately on the discovery.

A Tilton man has admitted to swapping children’s drugs at a residential facility, injuring two children.

Thomas Poirier, 41, of Tilton, pleaded guilty on Monday to charges dating back to December 2020.

Poirier worked at Spaulding Academy and Family Services, a residential facility in Northfield. Prosecutors said an investigation was launched when a nurse discovered a missing Ritalin prescription from a controlled medication cart.

Surveillance video shows Poirier inside the medication room, handling the cart. He is accused of taking Ritalin pills for several days and putting an unknown substance in their place.

According to the state, about 20 children, including nine under the age of 13, took the pills. Because they did not receive the medication they needed, two of the children suffered severe physical and psychological harm, prosecutors said.

Poirier pleaded guilty to two assault charges and one drug charge. He will be sentenced at a later date and prosecutors recommend a sentence of four to eight years in prison.

Prosecutors praised Spaulding for acting immediately on the discovery.

]]>
Global Migraine Drugs Market is expected to grow by USD 1 Billion during 2022-2026, accelerating at a CAGR of 5.74% during the forecast period https://atozinfandel.com/global-migraine-drugs-market-is-expected-to-grow-by-usd-1-billion-during-2022-2026-accelerating-at-a-cagr-of-5-74-during-the-forecast-period/ Mon, 21 Nov 2022 15:40:00 +0000 https://atozinfandel.com/global-migraine-drugs-market-is-expected-to-grow-by-usd-1-billion-during-2022-2026-accelerating-at-a-cagr-of-5-74-during-the-forecast-period/ NEW YORK, November 21, 2022 /PRNewswire/ — Global Migraine Drugs Market 2022-2026The analyst monitors the migraine medication market and it is poised to grow by $1 billion during the period 2022-2026, accelerating at a CAGR of 5.74% during the forecast period. Our Migraine Drugs Market report provides holistic analysis, market size and forecast, trends, growth […]]]>

NEW YORK, November 21, 2022 /PRNewswire/ —

Global Migraine Drugs Market 2022-2026
The analyst monitors the migraine medication market and it is poised to grow by $1 billion during the period 2022-2026, accelerating at a CAGR of 5.74% during the forecast period. Our Migraine Drugs Market report provides holistic analysis, market size and forecast, trends, growth drivers, and challenges, and vendor analysis covering around 25 vendors.

Read the full report: https://www.reportlinker.com/p02661025/?utm_source=PRN

The report offers up-to-date analysis regarding the current global market scenario, latest trends and drivers, and overall market environment. The market is driven by the increase in the number of patients suffering from migraine, the advent of regenerative drugs and the increasing advances in migraine medications.
The Migraine Drugs Market analysis includes end-user and type segments and geographical landscape.

The Migraine Drugs Market is segmented as follows:
Per end user
• Hospitals
• Retail
• Online

By type
• Preventive
• Abortion

By geographical landscape
• North America
• Europe
• Asia
• Rest of the World (ROW)

This study identifies the growth in the number of migraine treatment awareness programs as one of the major reasons for the growth of the migraine medication market over the next few years. Additionally, an increase in the availability of late-stage pipeline products and drug reformulations will drive significant demand in the market.

The analyst presents a detailed picture of the market through the study, synthesis and summation of data from several sources by analyzing the key parameters. Our Migraine Drugs Market report covers the following areas:
• Migraine Drugs Market Sizing
• Migraine Drugs Market Forecast
• Industry Analysis of Migraine Drugs Market

This robust vendor analysis is designed to help clients improve their position in the market, and in accordance with this, this report provides a detailed analysis of several major vendors in the Migraine Drugs market including Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, H Lundbeck AS, Johnson and Johnson, Merck and Co. Inc., Neurelis Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Sanofi SA, Winston Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., GlaxoSmithKline Plc, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. In addition, the Migraine Drugs Market analysis report includes insights into upcoming trends and challenges that will influence the growth of the market. It’s about helping businesses strategize and take advantage of all the growth opportunities ahead.
The study was conducted using an objective combination of primary and secondary information, including contributions from key industry participants. The report contains a comprehensive market and vendor landscape in addition to an analysis of major vendors.

The analyst presents a detailed picture of the market through the study, synthesis and summation of data from several sources by analyzing key parameters such as profits, prices, competition and promotions. It presents various facets of the market by identifying the major industry influencers. The data presented is comprehensive, reliable and the result of extensive research – both primary and secondary. Technavio’s market research reports provide a comprehensive competitive landscape and in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Read the full report: https://www.reportlinker.com/p02661025/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________
Contact Claire: clare@reportlinker.com
USA: (339)-368-6001
International: +1 339-368-6001

Quote

View original content: https://www.prnewswire.com/news-releases/the-global-migraine-drugs-market-is-expected-to-grow-by-1-bn-during-2022-2026– accelerating-a-cagr-du-5-74-during-the-forecast-period-301682741.html

SOURCE report link

]]>
Big Pharma targets $50 billion market for obesity drugs as demand soars https://atozinfandel.com/big-pharma-targets-50-billion-market-for-obesity-drugs-as-demand-soars/ Mon, 21 Nov 2022 04:00:04 +0000 https://atozinfandel.com/big-pharma-targets-50-billion-market-for-obesity-drugs-as-demand-soars/ When Novo Nordisk launched the weight-loss drug Wegovy last year, it recruited American rapper and actress Queen Latifah to lead an advertising campaign aimed at combating the stigma that often surrounds obesity treatments. Fast-forward a year and there are few signs of public reluctance to embrace the drug, which a late-stage clinical trial found resulted […]]]>

When Novo Nordisk launched the weight-loss drug Wegovy last year, it recruited American rapper and actress Queen Latifah to lead an advertising campaign aimed at combating the stigma that often surrounds obesity treatments.

Fast-forward a year and there are few signs of public reluctance to embrace the drug, which a late-stage clinical trial found resulted in patients losing an average of 15% of their body weight. Instead, the Danish company has become a victim of its own success. Growing demand and manufacturing constraints have caused widespread shortages of Wegovy.

The scarcity of the drug, which bears the generic name of semaglutide and is an appetite suppressant, forced Novo to temporarily suspend marketing and rethink its manufacturing strategy. It’s also been a chance for Eli Lilly, Amgen and several biotech companies developing similar obesity drugs to try to catch up in a market that analysts say could be worth $50 billion a year. 2030.

“This rocket launch, with a more or less vertical absorption curve, changes your robustness to handle problems,” Novo chief executive Lars Fruergaard Jørgensen told the Financial Times.

He said Novo had not anticipated Wegovy’s huge demand, basing its projections on the slower ramp-up in sales of Saxenda, its former obesity drug that helped patients lose about 5% of their body weight. The company aims to resolve its production issues by the end of the year, which will allow it to do more to promote Wegovy in the United States and launch in several European countries, Jørgensen said.

The rush to launch a new generation of drugs to fight obesity – a disease that affects an estimated 650 million people worldwide – has caused unease among some critics, who warn of their potential abuse and their Side effects. But most health experts say the drugs are expected to have a very positive impact on patients who are obese, a disease that can have devastating health consequences and goes largely untreated.

You see a snapshot of an interactive chart. This is probably because you are offline or JavaScript is disabled in your browser.

Obesity is linked to health problems such as heart disease, stroke, kidney disease and high blood pressure. But less than 1% of the estimated 71 million obese American adults used weight-loss drugs from 2012 to 2016, according to a report by the US Government Accountability Office.

Doctors say people are increasingly seeing obesity as a disease to be treated rather than some kind of moral decay or laziness, in part because of new drugs.

“Right now we’re seeing really dramatic demand for semaglutide. There are patients of mine that I can’t take on the drug,” said Dr. Fatima Stanford, an obesity medicine specialist at Massachusetts General in Boston, a teaching hospital affiliated with Harvard University. “You have to focus on increasing the supply.”

Stanford said patients are more receptive to taking drugs today than in the past due to their good safety profiles and higher rates of effectiveness, newer drugs capable of achieving loss of weight equivalent to bariatric surgery. But there is a need to educate physicians and private and public insurance plans to ensure reimbursement and drive uptake, she said.

Analysts predict that obesity drugs will be the next blockbuster pharmaceutical category, equivalent to the revolution in the treatment of high blood pressure in the 1980s.

“With conservative pricing assumptions, we believe global obesity sales could reach over $50 billion in 2030. This would move obesity from a $2.4 billion category to one of the top 12 therapeutic areas in terms of global spend,” said Morgan Stanley analyst Mark Purcell.

You see a snapshot of an interactive chart. This is probably because you are offline or JavaScript is disabled in your browser.


“Unlocking the Obesity Challenge: a >$50bn market”, a report co-authored by Purcell, predicts that the market will be driven by several factors: greater awareness that obesity drugs can save lives; removal of supply constraints; the role of social media in popularizing drugs; and a greater focus on weight loss in the fight against diabetes.

A four-week course of Wegovy has a list price of $1,349 per month, although patients with insurance that covers the drug pay less. Since patients have to take the drugs for life to ensure they don’t regain weight, obesity drugs are expected to generate stable revenue over long periods for drugmakers, analysts say.

Morgan Stanley expects Novo Nordisk and Lilly to capture about 40% of the market as they develop and launch up to a dozen obesity drugs currently in development. Several other biotech companies – Amgen, Altimmune, Zealand Pharma, Hanmi, Regor Therapeutics, Sciwind Biosciences and vTv Therapeutics – are in the early stages of drug development.

Last month, the US Food and Drug Administration granted fast-track designation to Lilly’s weight-loss drug Tirzepatide – a move the company says should lead to its approval next year. He successfully launched a formulation of the drug, which he dubbed Mounjaro, in May to treat type 2 diabetes at a list price of $974 for four weekly doses.

SVB Securities predicts strong demand for Tirzepatide when it is approved for obesity and warns it could face similar supply constraints as Wegovy. The investment bank predicts that Tirzepatide will generate around $26 billion in annual sales in 2030, of which around one-third relate to the treatment of diabetes and two-thirds to obesity.

Tirzepatide and Wegovy belong to a class of drugs known as glucagon-like peptide 1 (GLP-1) agonists, which were originally developed to help control blood sugar in people with diabetes. These drugs target an area of ​​the brain that regulates appetite and can cause significant weight loss in patients when given once a week by injection under the skin.

“I think [Mounjaro] will be a great opportunity for the company,” said David Ricks, chief executive of Lilly, citing the drug’s successful launch for the treatment of diabetes and its potential as a weight-loss drug.

“We’ve never seen a drug that had more than 20% weight loss before and that puts us in a unique category similar to gastric bypass surgery.”

In April, Lilly reported that Mounjaro caused an average loss of 15% in body weight at the low dose to 22.5% at the higher dose in a late-stage clinical trial. Patients taking Wegovy in a separate trial funded by Novo Nordisk lost around 15% of their body weight on average, with a third of patients losing more than 20%.

You see a snapshot of an interactive chart. This is probably because you are offline or JavaScript is disabled in your browser.


Social media endorsements by celebrities have become a driver of demand for weight-loss drugs, a trend that some doctors say exacerbates Wegovy’s supply shortage and may lead to misuse. Last month Tesla founder Elon Musk attributed his weight loss to ‘fasting’ and ‘Wegovy’, while weight loss strategies using Novo’s Ozempic – which is the same drug but approved to treat diabetes and available in lower doses – have gone viral on TikTok.

“This is a concern for all drugs that receive social media hype and are misinterpreted as a miracle drug,” said Dr. Robert Kushner, a professor at Northwestern University Feinberg School of Medicine. “They are not approved for slimming or just losing weight.”

Kushner said these prescription drugs require monitoring for tolerance and potential side effects. But he said their effectiveness was causing a “paradigm shift” in the way doctors treat obesity.

Weight loss drugs have a checkered history in the United States. The FDA has previously withdrawn the authorization of several drugs such as fenfluramine and dexfenfluramine due to life-threatening side effects. Trial results show that Wegovy and Tirzepatide can cause nausea, diarrhea, vomiting, constipation, and stomach pain. Both drugs also come with warnings that they may increase the risk of thyroid cancer, although so far this has only been found in animal studies.

Dr. Beverly Tchang, an endocrinologist and assistant professor of clinical medicine at Weill Cornell Medicine, said regulatory oversight is much better than it was in the 1960s, when an earlier generation of weight-loss drugs were approved.

“We have a better safety profile thanks to the regulations.”

Chang said some older doctors remain reluctant to prescribe weight-loss drugs for obesity, in part because of concerns about side effects from previous drugs. But she said the main obstacle to their adoption was the reluctance of private and public insurers to cover the costs.

Jørgensen said the company still needs to discuss with government payers – in the US and Europe – how obesity cannot always be solved with diet and exercise, and that drugs can save health systems money. In the United States, Medicare does not cover obesity treatments, but Jørgensen said he thinks that will change as people on the drugs retire and expect continued coverage.

“If you have had a long productive life and paid taxes, you also expect to have access to it. So I think it’s a matter of time. »

Lars Fruergaard Jorgensen
Lars Fruergaard Jørgensen, Managing Director of Novo Nordisk
]]>
Fight against counterfeit medicines: digital is the key https://atozinfandel.com/fight-against-counterfeit-medicines-digital-is-the-key/ Sat, 19 Nov 2022 06:30:00 +0000 https://atozinfandel.com/fight-against-counterfeit-medicines-digital-is-the-key/ By Dr. Gajendra Singh Medicines are important for us to cure illnesses. These can be prescription supplements or dietary supplements. They help prevent, treat disease and improve health. With the growing threat of counterfeit medicines prevalent around the world, ensuring authenticity is becoming the need of the hour. Nearly 10.5% of medicines sold worldwide are […]]]>

By Dr. Gajendra Singh

Medicines are important for us to cure illnesses. These can be prescription supplements or dietary supplements. They help prevent, treat disease and improve health. With the growing threat of counterfeit medicines prevalent around the world, ensuring authenticity is becoming the need of the hour. Nearly 10.5% of medicines sold worldwide are falsified, which has a negative impact on public health, pharmaceutical companies and a company’s reputation.

India’s date with fake and falsified drugs is no different. While India stands as one of the biggest market leaders, supplying and exporting generic drugs worth millions every year, the fake drug trade is tarnishing its image.

As the demand for drugs has increased during the COVID-19 pandemic, online pharmacies have largely benefited, leading to increased investment in this sector. However, the trade in fake drugs and essential medical products also increased during this period. Reports of fake vials of drugs like remdesivir have made headlines around the world. Even though counterfeiting is a major challenge for any industry, the sale of substandard and falsified medicines (SFFCs) has a greater impact as it affects human lives.

Challenges Facing the Healthcare Ecosystem

The sale of fake medicines that typically contain substandard or toxic active ingredients can negatively impact health outcomes and lead to morbidity and mortality. India-specific challenges that need to be addressed include the distribution of over-the-counter drugs (often without a valid prescription), the lack of insurance, and the enforcement of consistent investigations against manufacturers of fake drugs.

The Drug Controller General of India (DCGI) must work closely with the pharmaceutical companies and state authorities to eliminate the problem by following standard and defined protocols. When a complaint is filed and an investigation is conducted, the DCGI guideline labels the drug as “Not Standard Grade”, without specifying whether it is a substandard formulation or a bogus formulation. or falsified. Strict measures must be taken to punish those who manufacture and sell falsified or counterfeit medicines in the name of the original pharmaceutical company, which has no knowledge of them.

Moreover, the lack of quality control infrastructure makes it doubly difficult for authorities to impose strict oversight on the threat of counterfeiting in the pharmaceutical sector. Additionally, low consumer awareness and supply chain imbalances add to the burden. However, with the growing demand to put patient needs first, these infrastructural gaps need to be addressed and improved where possible.

Benefits of digital technology for safe access to medicines

As fake drugs pose dangers to India’s healthcare system and public health, corrective actions are being taken to revise manufacturing and supply chain discrepancies. The adoption of digital technology has been one of the measures taken to combat the sale of fake medicines. It also helps the industry to modernize and phase out SFFC drugs.

Digital track and trace technology can reinforce product authenticity and stop blatant copying. Advances in technology can also help businesses adopt features like serialization and unique packaging with scannable barcodes that can help with more consumer-focused content and better awareness of what to look for. These can also allow consumers to authenticate a product simply by using their phone.

In 2019, the Central Drugs Standard Control Organization (CDSCO) introduced a bill establishing a uniform QR code on drug packaging for ethical compliance and industry-wide quality control. Recently, the Department of Health released a bill titled “Drug, Medical Devices, and Cosmetics Bill-2022” which addresses potential shortcomings in the sale of drugs through online pharmacies. Since January 2023, the government has mandated the use of barcodes/QR codes on Active Pharmaceutical Ingredients (APIs), raw materials and packaging materials for brands available in the country.

The fight against pharmaceutical counterfeiting is also essential to reduce manufacturing losses and ensure patient safety. The pharmaceutical industry and government must act together to establish uniform testing mechanisms and regulatory frameworks and enable punitive actions against fraudulent retailers and agencies. Higher authorities, including CDSCO, the Department of Health and Family Welfare, and the Department of Trade and Industry, should also actively promote programs that encourage consumer awareness and empower pharmaceutical companies.

(The author is a public health expert. The opinions expressed are personal and do not reflect the official position or policy of FinancialExpress.com.)

]]>
SeaTac suspect charged with drug trafficking at Tukwila Transit Center https://atozinfandel.com/seatac-suspect-charged-with-drug-trafficking-at-tukwila-transit-center/ Fri, 18 Nov 2022 23:14:16 +0000 https://atozinfandel.com/seatac-suspect-charged-with-drug-trafficking-at-tukwila-transit-center/ From our sister site The Tukwila Blog: A suspect with at least 21 past warrants was charged this week with violations of the Uniform Controlled Substances Act and first degree unlawful possession of a firearm in Tukwila by the King County Attorney’s Office (KCPAO) . Defendant Ezekiel Demario Reynolds also has pending burglary 2 in […]]]>

From our sister site The Tukwila Blog:

A suspect with at least 21 past warrants was charged this week with violations of the Uniform Controlled Substances Act and first degree unlawful possession of a firearm in Tukwila by the King County Attorney’s Office (KCPAO) .

Defendant Ezekiel Demario Reynolds also has pending burglary 2 in Pierce County Superior Court and DWLS 2 in Kent Municipal Court.

“Based on the defendant’s criminal history, which includes violent offenses and his current active cases, the state is concerned that the defendant is likely to commit a violent offense,” prosecutors said.

Additionally, the charging documents state that the defendant’s term history includes 21 prior terms from 2015 to 2019; here is more information:

Due to ongoing violence and drug trafficking at the Tukwila International Blvd Transit Center located at 3651 Southcenter Blvd. (map below) King County Sheriff’s Office Transit Police and the Tukwila Police Department have teamed up to try to solve the crime problem.

During the summer of 2022, Metro 41 Transit Police Detectives from the Sheriff’s Office conducted surveillance in and around the Transit Center. Detectives observed the suspect at the transit center on numerous occasions near the north stairs. He was seen driving his car into the transit center parking lot near the north stairs, parking, mingling with people, and then driving back in his car.

“It does not appear that Reynolds was using the transit center for transit purposes,” police said. “While at the transit center, Reynolds was associating with people who were observed selling controlled substances.”

On August 25, 2022, a detective saw Reynolds at the AM/PM store across the street north of the Transit Center. He was sitting in the driver’s seat of another car, a black 1998 BMW 528i at the gas pumps. Reynolds’ driver’s door was open. Another known drug dealer in the area stood in the doorway of his driver. This dealer handed money to Reynolds, who took it, then within a minute poured some unknown items into the dealer’s hand. The suspect’s hand opened from a clenched fist position, and with his thumb up, he opened his hand from little finger to index finger. Police say this style of transaction showed he poured pills into the dealer’s hand. The trafficker left the AM/PM store and went straight to the transit center and mingled with other known drug traffickers on the north staircase of the transit center.

Detectives performed a Licensing Department check on Reynolds’ plates and found a recent report of him being sold as Ezekiel Berry. Per DOL, Berry is an AKA for Reynolds. A DOL check of Reynolds’ name revealed two outstanding warrants for his arrest, in Pierce County Superior Court for 2nd degree burglary and a Department of Corrections warrant for escape of custody. community for 3rd degree assault. DOL showed that Reynolds was recently convicted for Felony Eluding.

On October 21, 2022 at 5 p.m., another detective saw Reynolds’ BMW arrive at the transit center. Other detectives were alerted by radio. A detective saw the Reynolds parking lot on the west side of the transit center’s north staircase. He saw that Reynolds was the driver of his car and that he was the sole occupant.

Two deputies who were driving fully marked police cars and wearing KCSO department uniforms made contact with Reynolds as he sat in his car. A deputy activated the hazard lights of his police car. Reynolds got out of his car and ran east away from the deputies. A detective managed to disrupt Reynolds’ escape attempt and he was taken into custody. Reynolds’ arrest warrants were confirmed; however, he was denied the booking due to injuries sustained during the arrest.

Reynolds was released and his arrest warrants remain active. A Tukwila Police Narcotics K-9 sniffed out Reynolds’ vehicle while he was at the transit center. The K-9 alerted the BMW and she was seized for a search warrant.

On October 27, 2022, a detective requested and received a search warrant from King County Superior Court for Reynolds’ BMW. Detective searched the vehicle as per warrant and found a 9mm semi-automatic handgun, MDMA or ecstasy pills, (12) small blue pills inscribed with “M30” (suspected fentanyl) , a digital scale and $1,000 in cash.

The detective tested for MDMA/ecstasy using Narcotest 2 and 23 kits, and received a positive reaction for MDMA. The detective weighed the suspected MDMA without packaging at 3.51 grams. The amount of MDMA pills almost filled a small sandwich bag.

After cleaning the pistol, the detective found one 9mm bullet in the chamber and nine 9mm bullets in the magazine. He also saw that the serial number of the gun was erased.

The detective reviewed a copy of Reynolds’ criminal history and found that he had four felony convictions: in 2019 for attempted escape, in 2018 for taking a motor vehicle without permission, in 2017 for assault. done in the 3rd degree and theft in the 1st degree. Reynolds also received a misdemeanor conviction in 2017 for breaching a no contact/protective order. Each of these crimes prohibits Reynolds from owning, possessing, or purchasing a firearm.

Bail was set at $15,000.00 and KCPAO requested additional conditions that the suspect have no new violations of the law, possess no non-prescription controlled substances, possess no dangerous weapons or deadly, possess no firearms, appear at all future court dates when required to do so, and maintain contact with counsel.

At 6 a.m. on Thursday, November 10, 2022, Reynolds was arrested at his home in SeaTac. He was informed of his constitutional rights and committed to King County Jail.

]]>